| A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy (NCT00447421) | Eli Lilly and Company | 2007-02-01 |
| Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy (NCT00415363) | Eli Lilly and Company | 2006-12-01 |
| A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy (NCT00883181) | Amgen | 2006-11-01 |
| Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer (NCT00397293) | Ascenta Therapeutics | 2006-11-01 |
| Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy (NCT00375193) | Celgene | 2006-11-01 |
| Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer (NCT00388960) | Celgene | 2006-11-01 |
| Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer (NCT00374140) | Ahmad Tarhini | 2006-10-01 |
| Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer (NCT00363415) | Eli Lilly and Company | 2006-08-01 |
| A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer (NCT00349492) | Clinical Research Center for Solid Tumor, Korea | 2006-06-01 |
| Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer (NCT00454324) | UNC Lineberger Comprehensive Cancer Center | 2006-04-01 |
| Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC) (NCT00452634) | National Cancer Center, Korea | 2006-04-01 |
| Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. (NCT00319969) | Celgene Corporation | 2006-04-01 |
| Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) (NCT00286169) | Sumitomo Pharma Co., Ltd. | 2006-04-01 |
| A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (NCT00317200) | Hoosier Cancer Research Network | 2006-04-01 |
| Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer (NCT00294190) | SCRI Development Innovations, LLC | 2006-02-01 |
| Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED) (NCT00812266) | Danish Oncological Lung Cancer Group | 2006-01-01 |
| Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC) (NCT00418743) | Groupe Francais De Pneumo-Cancerologie | 2005-12-01 |
| Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer (NCT00116610) | Poniard Pharmaceuticals | 2005-06-01 |
| Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer (NCT00316433) | Swedish Medical Center | 2005-02-01 |
| Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer (NCT00216216) | Hoosier Cancer Research Network | 2005-01-01 |
| A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer (NCT00298688) | AstraZeneca | 2004-09-01 |
| An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation (NCT00132704) | Memorial Sloan Kettering Cancer Center | 2004-08-01 |
| Doxil Topotecan Doublet Cancer Study (NCT00252889) | Christiana Care Health Services | 2004-05-01 |
| Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) (NCT00080015) | Ipsen | 2004-03-12 |
| Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients (NCT00213798) | University Hospital, Strasbourg, France | 2003-12-01 |
| Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer (NCT01125995) | Samsung Medical Center | 2003-06-01 |
| Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer (NCT00065429) | ImmunoGen, Inc. | 2003-04-01 |
| A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa (NCT00119613) | Amgen | 2002-12-01 |
| Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide (NCT00290953) | Sanofi | 2002-10-01 |
| A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC (NCT00144989) | Haruhiko Fukuda | 2002-09-01 |
| The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) (NCT00043862) | GlaxoSmithKline | 2002-08-01 |
| Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors (NCT00178698) | The University of Texas Health Science Center, Houston | 2002-07-01 |
| Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC (NCT00156286) | University of Michigan Rogel Cancer Center | 2002-03-01 |
| A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage (NCT00168896) | Charite University, Berlin, Germany | 2001-10-01 |
| Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults (NCT00043927) | GlaxoSmithKline | 2001-04-01 |
| PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases (NCT02324296) | Azienda USL Reggio Emilia - IRCCS | 1998-12-01 |
| Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer (NCT06064500) | Amgen | |
| A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA (NCT04291937) | Jazz Pharmaceuticals | |
| Expanded Access to ABBV-706 (NCT07310277) | AbbVie | |
| Expanded Access to Rovalpituzumab Tesirine (NCT03503890) | AbbVie | |